Jupiter Neurosciences Expands CNS Pipeline with ALA-002 Licensing Deal Worth Up to $100M
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.
NOTRELOAD AI
Hasbro Raises Full-Year Outlook After Record Magic: The Gathering Quarter
Hasbro swung to a profit and raised its 2026 guidance after a strong second quarter led by Magic: The Gathering. Revenue jumped 16% to $1.14 billion, beating Wall Street estimates.
Utz Brands to Be Taken Private by Germany’s Intersnack Group in $2.9 Billion Deal
Utz will become privately held with 50/50 ownership alongside the Rice and Lissette founding family.
BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
Agios Ends Tebapivat Program in Sickle Cell Disease, Focuses on Mitapivat
Agios Pharmaceuticals announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile.
3M Raises Full-Year Guidance After Strong Q2 Earnings Beat
Adjusted organic growth hit 5.4% as Safety & Industrial surged.